In agonist-stimulated platelets, the integrin allb p3 (glycoprotein Ilb-llla) is converted from an inactive to an active fibrinogen receptor, thereby mediating platelet aggregation. With time after agonist addition, at least two events occur: fibrinogen becomes irreversibly bound to the platelet and, when stirring is delayed, platelets lose the ability to aggregate despite the presence of maximally bound fibrinogen. Because we previously identified an actively internalized pool of allb p3 in platelets, we explored the possibility that both of these events might result from the internalization of fibrinogen bound to active allb p3. Under conditions of irreversible fibrinogen binding, fluorescence microscopy showed that biotinylated fibrinogen is rapidly internalized ENTRAL TO THE maintenance of normal hemostasis is the ability of platelets to aggregate to form a platelet plug, thus preventing blood loss. Aggregation is mediated largely by the binding of the adhesive protein, fibrinogen, to integrin aIlb , B 3 (glycoprotein IIb-IIIa) on the platelet surface.
by activated platelets to a surface-inaccessible, intracellular pool. Flow cytometric analysis showed that the observed loss in accessibility to extracellular probes immediately precedes a loss in ability of the platelets to aggregate. Moreover, prevention of irreversible fibrinogen binding results in a prevention of internalization and a retention of aggregation capacity. Thus, the internalization of fibrinogen from the activated platelet surface appears to contribute not only to the irreversible phase of fibrinogen binding, but also to the downregulation of platelet adhesiveness. Fibrinogen internalization is therefore likely to represent a fundamental regulatory mechanism that modulates platelet function. 0 1996 by The American Society of Hematology.
fibrinogen uptake by activated platelets immediately precedes a loss in their ability to aggregate upon stimng, whereas inhibition of fibrinogen uptake correlates with retention of aggregation capacity. Thus, the present study provides evidence that fibrinogen internalization by activated platelets contributes to the return of stimulated platelets to a nonadhesive state.
MATERIALS AND METHODS

Chemicals and reagents.
Bovine serum albumin (BSA; once recrystallized, essentially globulin free), prostaglandin Iz (PGI,), plasmin, and poly-L-lysine were purchased from Sigma Chemical CO (St Louis, MO). For binding studies, BSA (Pentax, Fraction V) was purchased from Miles Laboratories (Kankakee, IL). Paraformaldehyde was obtained from Polysciences (Warrington, PA). Sepharose CL-2B and PD-IO columns were obtained from Pharmacia, Inc (Piscataway, NJ). Triton X-l00 was purchased from J.T. Baker Chemicals (Phillipsburg, NJ). Apyrase was the generous gift of Dr R.L. Kinlough-Rathbone (McMaster University, West Hamilton, Ontario, Canada). The apyrase stock had an ADPase activity of 7.14 X IO"" mol ADP hydrolyzedminhl apyrase and an ATPase activity of 5.55 X IO"" mol ATP hydrolyzedmidmL. Other chemicals, unless indicated, were of reagent grade.
Platelet preparation. Whole blood was obtained from healthy, aspirin-free volunteers. The first I mL of blood was discarded and the remainder was drawn into a solution of 37°C acid citrate dextrose (1.4 mU8.6 mL blood), containing 150 nmoUL PG12 (Sigma). Platelet-rich plasma (PRP) was isolated by centrifugation at 180g for 20 minutes. In studies using gel-filtered platelets, PRP obtained from 20 mL of whole blood was applied to a 2.5 X 10 cm column of Sepharose CL-2B (Pharmacia) pre-equilibrated at room temperature (RT) with CaZ'/Mg2'-free Tyrode's-HEPES buffer (138 m m o n NaC1, 12 mmol/L NaHCO,, 10 mmol/L KCI, 5.5 mmoUL glucose, 0.36 mmol/L Na,HPO,, 0.35% BSA, and 10 mmoVL HEPES, pH 7.4). and 1.5-mL fractions were collected into tubes containing 15 FL of a 1 : 100 dilution of the apyrase stock. The platelet concentration was adjusted to 2 to 4 X 10X/mL. Platelets were tested for their ADP-dependent aggregation response before each experiment. Platelets in the presence of 1.4 mg/mL fibrinogen, 2 mmol/L CaCh. and I mmol/L MgClz were stimulated with ADP (70 pmol/L) under stirring conditions (1,200 rpm) and aggregation was monitored on a platelet aggregometer (Chrono-log, Havertown, PA).
Fibrinogen labeling. Fibrinogen was isolated from fresh human plasma by the method of Kazal et all4 with a gelatin-Sepharose chromatography step to remove contaminating fibronectin and was dialyzed into Ca2+/Mg2+-free Tyrode's buffer lacking BSA. Fibrinogen was labeled with "'1 (1 mCi), using chloramine T as described"; with NHS-biotin (Pierce, Rockford, IL)"; or with both. For labeling For personal use only. on October 23, 2017. by guest www.bloodjournal.org From with biotin, fibrinogen was first dialyzed into a buffer of 0.1 moVL NaHC03 and 0.1 moVL NaCl, pH 8.2. The concentration of fibrinogen was adjusted to 1.5 mg/mL and sulfo-NHS-biotin was added dry at 0.2 mg/mL of solution. The solution was mixed on an orbital mixer (Adams Nutator) for 30 minutes at RT. Uncoupled biotin was separated from biotinylated-fibrinogen on a PD-10 column (Pharmacia) blocked with BSA and pre-equilibrated in Ca*+/Mg*+-free Tyrode's-HEPES buffer lacking BSA. The extent of biotinylation was determined by Method I, as described by the manufacturer. Acetone precipitation of fibrinogen showed that 17 to 25 mol of biotin was present per 1 mol of fibrinogen. The concentration of biotinylated fibrinogen was determined on Coomassie-blue stained sodium dodecyl sulfate (SDS) gels by densitometry, relative to fibrinogen standards. For flow cytometry studies, fibrinogen was conjugated with fluorescein isothiocyanate (FITC) using FITC-celite as previously de~cribed.'~ Fibrinogen (labeled and unlabeled) was centrifuged for 10 minutes in a microfuge (Haake Buchler Instruments, Inc, Saddle Brook, NJ) at 10,500g before use. In two to three experiments that directly compared the irreversible binding properties of '251-biotinylated fibrinogen to 'ZSI-fibrinogen, we found that 39.5% and 60.8% of '251-biotinylated fibrinogen versus 39.2% and 62.2% of '251-fibrinogen became irreversibly bound at 10 minutes and 60 minutes, respectively. These data confirm previous observations that biotinylated fibrinogen retains properties of the native molecule.'' Fibrinogen binding. Binding of '251-fibrinogen to platelets was performed in a manner similar to that described by Marguerie and Plow." Briefly, gel-filtered platelets (5 to 10 X 107/mL final concentration) were added last to an incubation mixture containing '*'Ifibrinogen (0.1 to 0.35 mg/mL) in a Tyrode's buffer that included 2.5 mmoVL CaCI2, 1.25 mmol/L MgCI2, and 0.6% BSA with ADP (70 pmoVL), and the platelets were incubated at RT without stimng for various times as indicated in the figure legends. Total platelet hound fibrinogen was quantified by centrifuging the platelets (40 pL) through 0.4 mL of 20% sucrose in Tyrode's buffer with 1% BSA for 2 minutes at RT and measuring the radioactivity associated with the platelet pellet. Irreversible fibrinogen binding for any given time point was quantified by adding EDTA (1 2 mmol/L) at that time to initiate dissociation of reversibly bound fibrinogen and, 30 minutes later, centrifuging the platelets through sucrose as above. Nonspecific binding was similarly quantified except that EDTA was added at time 0 to the platelet samples. EDTA added at time 0 for 5 minutes resulted in the same minimal amount of nonspecific binding as did EDTA added for 60 minutes. Specific binding was calculated by subtracting the nonspecific binding from total binding.
'"I-AP-3 binding studies. In studies designed to quantitate the number of aII,& molecules on the platelet surface under conditions of agonist-induced fibrinogen uptake, gel-filtered platelets were incubated for increasing periods of time with 10 pmoVL ADP in the presence of 50 nmoVL fibrinogen at RT. Internalization was inhibited by rapidly diluting samples at various time points with a 6.4-fold dilution of ice-cold buffer, and the total number of all& molecules/ platelet was determined by direct binding of monoclonal antibody (MoAb) '"I-AP-3 (50 nmol/L; a monoclonal anti-& antibody that does not inhibit fibrinogen binding") for 1 hour at 4°C. Plateletbound Iz5I-AP-3 was separated from unbound MoAb by centrifugation through sucrose, as described above. Nonspecific binding was determined by the addition of a 16-fold excess of unlabeled AP-3 along with "'1-AP-3. Specific binding of Iz5I-AP-3 is reported as a function of the incubation time of the platelets with ADP and fibrinogen at RT.
Fluorescence microscopy. In experiments parallel to those described for fibrinogen binding, platelets were incubated with biotinylated fibrinogen for 1, 10, or 60 minutes in the presence of 70 pmol/L ADP. After centrifugation at 14,000g for 5 minutes through 30 mL of sucrose, platelet pellets were resuspended in 1 mL of Ca2+/ Mg2+-free Tyrode's buffer lacking BSA. Platelets were subsequently fixed with 1% paraformaldehyde on ice for 1 hour. Unreacted aldehyde was blocked with NH,,CI-Tris-buffered saline, pH 7.4, and the platelets were permitted to settle on polylysine-coated glass coverslips. To visualize potential intracellular pools of biotinylated fibrinogen, fixed platelets were treated with 0.1% Triton X-100 for 3 minutes to render them permeable. Permeable or intact platelets were rinsed with Tris-buffered saline containing 0.1% BSA and were incubated for 20 minutes at RT with rhodamine-avidin (Vector Laboratories Inc, Burlingame, CA). Staining specificity was assessed in control samples incubated with free biotin only or with biotinylated fibrinogen in the presence of a 90-fold excess of unlabeled fibrinogen. Based on previous experience, the limit of detection of surfacebound molecules by immunoflourescence microscopy (ie, bound fibrinogen) is approximately ~2 , 0 0 0 molecules/platelet (J.D. Wencel-Drake, unpublished observations).
In studies using plasmin, platelets incubated with biotinylated fibrinogen were stimulated with 20 pmoVL ADP for 30 minutes at RT in the absence of stirring and allowed to internalize fibrinogen. After uptake, samples were centrifuged through sucrose and resuspended in BSA-free Tyrode's-HEPES buffer with 1 mmollL CaCI2. Samples were subsequently treated with buffer or 2% NaNl for 15 minutes at RT, washed, and then exposed to either buffer or 0.5 U/ mL plasmin for 30 minutes at RT. After fixation, platelets were permeabilized with lysophosphatidylcholine and counterstained with rhodamine avidin.
In double-label experiments, platelets incubated with biotinylated fibrinogen and MoAbl5 (an anti-& antibody that does not inhibit fibrinogen binding*') were stimulated with 100 pmoVL thrombin receptor agonist peptide (TRP) corresponding to the tethered ligand sequence SFLLRNPNDKYEPF" for 30 minutes at RT in the absence of stirring and allowed to internalize fibrinogen. After uptake, samples were fixed and either left intact or permeabilized with lysophosphatidylcholine and counterstained with rhodamine avidin and fluorescein goat anti-mouse IgG (Sigma) and mounted on a droplet of FITC-Guard (Testog Inc, Chicago, IL). Platelets were viewed with a Jenaval phasehluorescence microscope (Jenoptik, Jena, GmbH, Germany) equipped with an HBO 50-W mercury lamp, IVFl epifluorescence condenser with BP 485, BP 546 excitation filters, and BP 520-560, LP590 barrier filters. Platelets were photographed with Tri-X panchromatic film.
Flow cytometry. Unshed, washed platelets were stimulated with TRP (100 pmol/L) at 22°C in the presence of FITC-fibrinogen (1.47 pmoVL). At a variety of time points, samples were rapidly diluted 1:lO with 4°C buffer and immediately placed on ice to halt further redistribution of aIlb &FITC-fibrinogen complexes. Samples were analyzed on a Becton Dickinson FACStar analyzer (Becton Dickinson, San Jose, CA) formatted for single-color analysis. The fluorescence channel was set at logarithmic gain and was calibrated with 2-pm Calibrite Beads (Becton Dickinson). Acquisition was gated using a lower limit threshold that excluded background scatter. Values acquired reflect the mean fluorescence intensity for 10,000 events. After analyses for log green fluorescence, rabbit antifluorescein was added to each tube, and the same samples were reanalyzed for residual unquenched fluorescence. Because the cells were diluted in ice-cold buffer and maintained at 4°C before FACS analysis, access of the quenching antibody is limited to extracellular/surfaceassociated fluorescein. We therefore have interpreted protection from quenching by antifluorescein as evidence of internalization.
To calculate the percentage of surface-associated FITC-fibrinogen, logarithmic FACS data, in arbitrary fluorescence units, were converted to linear values while being collected. The amount of quenched fluorescence was then calculated as the difference between total fluorescence and the residual unquenched fluorescence present 
RESULTS
Contribution of fibrinogen internalization to irreversible fibrinogen binding. We previously identified a mobile pool of a l l h that appears to be internalized in resting platelets via the formation of endocytic vesicle^."^^' These results led us to evaluate the localization of fibrinogen bound to a f l h on activated platelets. We activated platelets with ADP in the presence of '"1-fibrinogen. followed by the addition of excess EDTA or control buffer. As shown in Fig Fig 1 were mimicked using biotinylated fibrinogen. Platelets were then fixed and either left intact or permeabilized with Triton X-IO0 and subsequently stained with rhodamine-avidin to visualize the biotinylated fibrinogen. With resting platelets, there was no surface or intracellular staining of biotinylated fibrinogen (Fig 2a and b) . Similarly, ADP-stimulated, fixed platelets showed no detectable rim staining pattern, for bound biotinylated fibrinogen (Fig 2c. e, and g ), a rim pattern being characteristic of surface localization. In contrast, parallel samples permeabilized with Triton X-100
showed a time-dependent increase in intracellular labeling (Fig 2d, f , and h), suggesting that bound fibrinogen was internalized. As early as 1 minute, biotinylated fibrinogen appeared intracellularly in discreet pinpoints of labeling (Fig  2d) , which, with time, increased in number and size (Fig 2f  and h ). When EDTA was added 60 minutes after platelet activation to remove reversibly bound biotinylated fibrinogen, the fluorescent staining pattern of permeabilized platelets was similar to that observed for total biotinylated fibrinogen binding (Fig 3b v Fig 2h) . When the binding of biotinylated fibrinogen was initiated in the presence of a 90-fold excess of unmodified fibrinogen, no surface or intraplatelet staining was observed (Fig 3c and d) , further confirming the specificity of the observed staining. Moreover, platelets incubated with free biotin remained unlabeled, showing that the observed staining pattern did not result from nonspecific uptake of biotin (Fig 3e and f) . Finally, proteins from platelets with irreversibly bound biotinylated fibrinogen were electrophoresed on reduced SDS-polyacrylamide gels, transferred onto nitrocellulose, and probed with HRP-avidin. These analyses showed no apparent difference in electrophoretic mobility between unbound biotinylated fibrinogen and platelet-associated biotinylated fibrinogen, confirming that the biotinylated fibrinogen was not proteolytically modified (data not shown). These data raise the possibility that irreversible fibrinogen binding may occur as a result of fibrinogen sequestration to an intracellular pool, thereby rendering it inaccessible to antibodies, inhibitory peptides, or EDTA.
Conversely, Peerschke"." has suggested that fibrinogen bound to activated platelets remains on the surface because it is accessible to digestion by plasmin. However, plasmin has been shown to activate platelets, inducing a-granule secretion and redistribution of aIIbP3.2s~2X and thus may induce the re-expression of internalized fibrinogen on the platelet surface. To test this possibility, gel-filtered platelets augmented with 200 nmol/L biotinylated fibrinogen were activated with 20 pmol/L ADP for 30 minutes at RT to stimulate fibrinogen binding and internalization. After an additional incubation in the presence or absence of plasmin (0.5 U/mL) for 30 minutes at RT. platelets were fixed, permeabilized, and counterstained with rhodamine avidin. In the absence of plasmin, the typical staining pattern for internalized biotinylated fibrinogen was observed (Fig 4a) . Treatment of parallel samples with plasmin before fixation essentially eliminated the previously observed intracellular staining (Fig 4b) . However, metabolic inactivation of platelets with NaN3. after internalization of biotinylated fibrinogen but before plasmin treatment, resulted in a retention of intracellular biotinylated fibrinogen (Fig 4d) . These data suggest that the ability of plasmin to cleave irreversibly boundinternalized fibrinogen in live (metabolically active) cells most likely stems from the secondary ability of the enzyme to induce the redistribution of fibrinogen andor all&-fibrinogen complexes to the platelet surface, where fibrinogen becomes accessible for digestion.
Internalization of jbrinogen bound to correlates with loss of platelet aggregation. We next examined the possibility that rapid intracellular sequestration of fibrinogen in activated platelets could explain the observation that platelets stimulated with an agonist before initiation of stirring exhibit a time-dependent loss in their aggregation response despite the presence of maximally bound fibrin~gen."~ To investigate whether internalization of bound fibrinogen is responsible for the decreased ability of agonist-stimulated platelets to aggregate when initiation of stirring is delayed, we first established a time course for loss of the aggregation response. Platelets were stimulated with a thrombin receptor agonist peptide (TRP) corresponding to the tethered ligand sequence (SFLLRNPNDKYEPF)." TRP ( 1 0 0 pmol/L) was added to unstirred platelets, after which stirring was initiated at varying times and the aggregation response was recorded. As illustrated in Fig 5a, the aggregation response was lost with time, confirming that TRP elicits a similar response to that reported for ADP, epinephrine, and thrombin.'" The observed failure of platelets to aggregate to TRP was not due to a lack of platelet viability with prolonged in vitro incubation times because subsequent stimulation of the same platelets with a different agonist (ADP) elicited an aggregation response (Fig 5b) . A different agonist (ADP) was used to assess viability because a second stimulation by TRP in the presence of stirring failed to elicit an aggregation response, as expected, due to desensitization of the thrombin receptor' (Fig 4b) .
To investigate a possible relationship between the timedependent loss of the aggregation response and internalization of bound fibrinogen in unstirred, stimulated platelets, we used flow cytometry (FACS). For these studies, fibrinogen was directly conjugated with FITC. Previous detailed studies by Hantgan*' have shown that FITC labeling of fibrinogen does not alter its clottability or fibrin assembly function or the rate, extent and specificity of binding to platelets. In preliminary studies, FITC-fibrinogen (0. ice to halt further redistribution of allhPZ-FITC-fibrinogen complexes. After FACS analyses for fluorescein fluorescence, rabbit antifluorescein was added to each tube and the same samples were reanalyzed for residual unquenched fluorescence. Because (Y& internalization is inhibited at 4°C,17.'2 access of the quenching antibody is limited to surface-associated fluorescein. As expected. FITC-fibrinogen bound to unstirred TRP-activated platelets with time (Fig 7,  0) . Despite fibrinogen binding to these platelets, parallel samples preincubated with TRP for similar time points before the initiation of stirring showed a time-dependent loss of the aggregation response (a). These data suggest that the loss of aggregation response does not result from the dissociation of bound fibrinogen. Because we have hypothesized that internalization of bound fibrinogen modifies the platelet aggregation response, we determined the relative amount of FITC-fibrinogen present on the platelet surface. A plot of the percentage of surface-associated, antibodyaccessible FITC-fibrinogen (calculated as described in the Materials and Methods) showed a loss of FITC-fibrinogen from the platelet surface that preceded the observed loss of aggregation (A). These data suggest that, 60 minutes after the initiation of stimulation in the absence of stirring, fibrinogen is maximally bound, yet platelets fail to aggregate once stirring is initiated. The demonstration that the loss of FITCfibrinogen from the platelet surface is followed by a loss of aggregation capacity suggests that internalization of fibrinogen bound to allhP3 serves to modulate platelet function.
These data also suggest that as much as 50% of fibrinogen bound to all& can be removed from the platelet surface before the extent of platelet aggregation is significantly affected. This finding is in keeping with aggregation data obtained from studies of platelets from patients with type I Glanzmann's thrombasthenia. an inherited disorder in which homozygotes with little or no (YllhP3 show minimal or absent platelet aggregation. However, heterozygotes, which express only 50% to 60% of the normal amounts of a l l h p 3 , exhibit normal aggregation responses."'."' Similarly, it has been proposed that 50%. but not IO%, of the normal levels of al& is required for platelet plug formation and other plateletassociated hemostatic responses."' Thus, these studies and the present work suggest that platelets have an excess of allhPz that is well above the amount required to support full aggregation and that there is a threshold level of fibrinogenbound allhP3 that must be removed from the platelet surface before affecting the extent of aggregation.
To evaluate whether internalization of bound fibrinogen in unstirred, stimulated platelets results in a net loss of a[[& from the surface, gel-filtered platelets augmented with unlabeled fibrinogen were activated with IO pnol/L ADP for various times at RT to allow fibrinogen binding and internal- staining for biotinylated fibrinogen observed in Fig 9b and d . despite excess extracellular biotinylated fibrinogen, suggests that cullhp3 returning to the surface is either unactivated or deactivated. Although the lack of staining could be due to occupancy of a & by endogenous (unlabeled) fibrinogen, the fact that these platelets fail to aggregate once stirring is initiated (data not shown) makes this interpretation less likely. Thus, cycling of bound fibrinogen from the platelet surface to an intracellular pool is apparently responsible for the loss of aggregation response in unstirred, stimulated platelets as well as the development of irreversible fibrinogen binding.
Based on these results, we reasoned that agents that fail to support the development of irreversible binding should similarly fail to stimulate internalization of bound fibrinogen. Moreover. we predicted that, under these conditions, bound fibrinogen would remain on the platelet surface, where it would be available to participate in cell-cell contact after the initiation of stirring, thereby preventing the loss of aggregation response observed in unstirred, stimulated platelets. To test these hypotheses. delayed stirring experiments were repeated in the presence or absence of Zn", because previous studies have shown that stimulation of platelets with ADP or thrombin in the presence of Zn" fails to support the development of irreversible fibrinogen binding." As shown in Fig IO, 
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L) for 30 minutes in the absence of Zn" typically fail to aggregate once stirring is initiated (lower trace). In contrast, inclusion of ZnClz (0.6 mmol/L) in the incubation mixture resulted in a retention of aggregation response in unstirred, TRP-stimulated platelets (Fig 10, upper trace) .
In parallel samples, we investigated the effect of Zn2+ on the ability of unstirred, TRP-stimulated platelets to internalize biotinylated fibrinogen using immunofluorescence microscopy. In these studies, unstirred, gel-filtered platelets augmented with biotinylated fibrinogen (430 nmol/L) were stimulated with TRP (100 pmol/L) in the presence or absence of ZnCI2 (0.6 mmol/L) for 30 minutes, at which time samples were fixed and either left intact or permeabilized with Triton X-100 and subsequently stained with rhodamineavidin. In the absence of Zn", intact platelets showed no detectable surface staining for biotinylated fibrinogen ( Fig  I la) , whereas permeabilized cells showed extensive intracellular staining for biotinylated fibrinogen (Fig 1 Ib) . In contrast, inclusion of Zn" in the incubation mixture resulted in the appearance of surface labeling of intact cells for biotinylated fibrinogen (Fig 1 IC) . Permeabilized platelets also show a rim staining pattern (Fig 1 Id) suggesting that biotinylated fibrinogen was largely excluded from the cell interior. Taken collectively, these results suggest that the ability of platelets to internalize fibrinogen-bound (Yllh O3 downregulates platelet aggregation. Conversely, the inhibition of internalization apparently results in the maintenance of aggregation capacity. Thus, these results suggest that internalization of fibrinogen-bound all,, p3 represents a fundamental regulatory mechanism that modulates platelet function.
DISCUSSION
In the present study we have observed that bound fibrinogen is rapidly internalized by agonist-stimulated platelets. In addition, fibrinogen internalization correlates with ( I ) the development of irreversible fibrinogen binding to stimulated, 609 unstirred platelets and (2) a loss in the ability of these platelets to aggregate on initiation of stirring, despite the presence of maximally bound fibrinogen. Thus, internalization of fibrinogen by activated platelets is likely to contribute to or account for both of these events. Based on these results. we propose that fibrinogen redistribution via internalization represents a regulatory mechanism enabling platelets to rapidly clear reactive, surface-associated ligand.
Stimulated fibrinogen binding is critical in platelet aggregation, a process central to hemostasis and thrombosis. Moreover, platelet aggregation can be regulated at the level of (Yllh p3 activation or of fibrinogen binding to (Yl&. ' The work reported here suggests a third potential level of regulation of platelet aggregation, ie, the internalization of plateletbound fibrinogen. The observed inaccessibility of bound fibrinogen to rhodamine-avidin, except on membrane permeabilization, suggests that platelets redistribute bound fibrinogen to a membrane-bound intracellular pool. Moreover, the accumulation of fibrinogen into this inaccessible pool is time-dependent, as are the phenomena of irreversible fibrinogen binding and the progressive loss of aggregation capacity. Thus, whereas previous studies have suggested that the development of irreversible fibrinogen binding, loss of accessibility to antifibrinogen antibodies. and a related loss in aggregation capacity are due to a qualitative change in surface bound fibrinogen,"."." the present studies provide an alternative interpretation, namely, that these phenomena could occur as the result of internalization of bound fibrinogen. However, it should be noted that our studies do not suggest that an irreversible interaction between platelet One possibility raised by the present studies is that internalization of bound fibrinogen may occur as a consequence of receptor-mediated endocytosis. Such internalization would readily explain the loss of fibrinogen dissociability and accessibility. Conversely, Peerschke"*23 has interpreted the accessibility of irreversibly bound fibrinogen to digestion by plasmin as evidence of surface localization. However, plasmin is known to activate platelets by inducing a-granule secretion and redistribution of aIb p3.25-28 Furthermore, we have shown that irreversibly bound fibrinogen is susceptible to plasmin digestion only in metabolically active cells. Taken collectively, these data suggest that the ability of plasmin to cleave irreversibly boundinternalized fibrinogen most likely stems from the secondary ability of the enzyme to induce the redistribution of fibrinogen andor a,&-fibrinogen complexes to the platelet surface, where fibrinogen becomes accessible for digestion. Perhaps more importantly, these studies suggest that internalized fibrinogen can be recycled back to the platelet surface in response to secondary stimulation.
In related studies, megakaryocytes have been shown to internalize fibrinogen in an aIb &dependent manner, resulting in the transport of fibrinogen to secretory a-granbrinogen to guinea pigs results in the appearance of labeled fibrinogen in the a-granules of megakaryocytes and platelet~.'~.~'' Similarly, in humans, administration of fibrinogen to an afibrinogenemic patient resulted in the elevation of platelet fibrinogen at a rate too rapid to be accounted for by megakaryocyte uptake of fibrinogen alone, thus implicating the direct uptake of fibrinogen by circulating platelets. 38 The observation that platelets from patients with Glanzmann's thrombasthenia, ie, platelets with little or no functional a l l b P3, show a corresponding decrease or lack of platelet agranule fibrinogen additionally supports an &-mediated pathway of endocytosis in platelets?* Moreover, ultrastmctural studies have showed that antibody-tagged (YlIb p3 redistributes to a-granules of unstimulated platelet^.^^ Finally, recent studies in our laboratory using monoclonal anti-allb p3 antibodies and a high-affinity RGD-containing ligand show that aIb p3 is internalized in resting platelet^.'^^" Taken collectively, these studies and the present work strongly support the hypothesis that internalization of fibrinogen by platelets occurs via an amfi3-dependent endocytic mechanism.
Fibrinogen mediates platelet aggregation by bridging integrin alb f i 3 molecules on adjacent platelets." Because internalized fibrinogen is inaccessible to antibody (R, = 49 A4') probes, it is almost certainly inaccessible to a~b p3 (R, = 74 A46) on other platelets. Moreover, there is a close temporal coincidence between loss of platelet aggregation and loss of fibrinogen acces~ibility.'~*'~ In addition, when loss of fibrinogen accessibility is prevented by pretreatment with chymotrypsin, cytochalasin D,I3 or Zn" (Figs 10 and 1 l) , the timedependent loss of platelet aggregation is also prevented. Thus, the internalization of fibrinogen reported here is likely to be involved in the downregulation of platelet aggregation. Furthermore, because stimulation of TRF' desensitized platelets with ADP resulted in aggregation, these studies might ules.18.38-41 In addition, the administration of biotinylated fialso suggest that, after stimulation by a second, different agonist, newly internalized fibrinogen is re-expressed on the platelet surface, where it can participate in aggregate formation. This possibility is supported by the present studies with plasmin that show that internalized fibrinogen can be reexpressed on the platelet surface. Alternatively, subpopulations of (Yllb p3 receptors may be activated by stimulation with different agonists. These receptors may represent a previously unactivated subpopulation of aImp3 andor a previously activated subpopulation that has returned to the surface in an unactivated state. This possibility is supported by the demonstration that albP3-fibrinogen complexes are rapidly internalized and apparently replaced on the surface with unoccupied and therefore either unactivated or deactivated (~1 J 3 . Additional experiments are required to determine whether these represent alternative or concurrent events.
Our observation of fibrinogen internalization by activated platelets is consistent with an emerging model of functionally mobile integrin receptors. In recent studies on vascular integrins, it has been reported that (YIlb p3, a, P3, a, p5, ah P4, and aM p2 (Mac-l) undergo endocytosis and cycling, whereas a3 PI, a4 PI. as PI, a 6 PI, and aL Pz (LFA-1) do so much more slowly.17~22~47~52 These studies suggest that the key determinant of whether an integrin cycles is an intrinsic property of the particular integrin rather than a particular cell type.48 Although the physiologic/pathologic significance of integrin cycling is not clearly understood, cycling of a5 PI has been suggested to mediate cell migration and spread- but fail to internalize biotinylated fibrinogen (Fig 2b) argues against this possibility. Another possibility is that fibrinogen uptake might occur via fluid-phase pinocytosis without the requirement of binding. If fluid-phase pinocytosis contributed significantly to fibrinogen uptake, then conditions that allow (Y[[b o3 internalization in platelets (eg, incubation with an RGD ligand'') should also allow fibrinogen uptake. However, incubation of platelets with RGD peptides and Iz5I-fibrinogen completely inhibits any association of '*%fibrinogen with platelets, thereby arguing against pinocytosis as an internalization mechani~m.'~ Thus, in the absence of pinocytosis, uptake of fibrinogen that occurs in platelet activation that facilitate fibrinogen binding and UPtake. The observation that in vivo, older platelets exhibit a loss of membrane as well as a-granule contents,56 s~ppofis the concept of recurrent cycles of circulating platelet activavivo18,38,s4-ss most likely involves transient mild cycles of For personal use only. on October 23, 2017. by guest www.bloodjournal.org From tion and recovery. Additionally, platelets have been shown to become activated by shear stress in in vitro flow systems57 and to recover from mild activation, as evidenced by their ability to undergo reversible activation or aggregation in vitro either spontaneously or more rapidly on exposure to naturally occumng platelet antagonists such as PG12 or nitric ~x i d e .~' .~~ Consequently, fibrinogen uptake itself could aid in the process of platelet recovery from stimulation due to a rapid clearing of this adhesive protein from the platelet surface.
In conclusion, our results suggest that fibrinogen can be rapidly internalized by ADP-stimulated platelets to a nondissociable, antibody-inaccessible, intracellular pool. The correlation of internalization with a loss of aggregation response suggests that loss of aggregability of unstirred platelets is due to fibrinogen internalization. Thus, q l b B, internalization, which downregulates surface fibrinogen in circulating platelets appears to represent a novel antithrombotic mechanism.
